The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited GNI armamentarium. Despite the launch of novel antibiotics, such as AbbVie / Pfizer’s Avycaz / Zavicefta, Merck & Co.’s Zerbaxa and Recarbrio, and Shionogi’s Fetroja / Fetcroja, unmet need remains for additional treatment options with novel mechanisms of action and with efficacy in patients with drug-resistant infections, which are associated with high rates of mortality. Although the market is heavily genericized and cost-containment measures have limited the commercial success of emerging therapies, innovative push-and-pull market approaches such as value-based pricing (VBP) and de-linked drug reimbursement models promise to encourage and support future antibiotics development.
QUESTIONS ANSWERED
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: 29 country-specific interviews with thought-leading infectious disease specialists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed cases of GNIs by country, segmented by key infections (HABP / VABP / HCAP, CSSSI / SSI, cIAI, BSI, and UTI), pathogens (E. Coli, Pseudomonas, Acinetobacter, Klebsiella), and resistance types.
Forecast: 10-year, annualized, drug-level sales and patient share of key GNI therapies through 2032, segmented by brands / generics, geography, and five key infection types
Emerging therapies: Phase 3/PR: 5+ drugs; Phase 2: 15+ drugs; coverage of select early-phase products
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.